RxDoctor Payments Data

Nicholas Urrutia, MD

Family Medicine · Hanford, CANPI 1205171378

Payments from drug & device makers

$1,102in general payments, 2019–2025

Across 75 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$492
  • Novo Nordisk$128
  • Merck$115
  • Sumitomo Pharma America, Inc.$71
  • AbbVie$61
  • Boston Scientific$57
  • plus $180 from 9 others

What the payments were for

  • Food & beverage$1,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,102 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$77,531
Medicare patients
150
Services billed
889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin140$161,907
JanuviaSitagliptin Phosphate60$83,267
EliquisApixaban114$65,350
OzempicSemaglutide63$59,938
TradjentaLinagliptin69$57,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$26,155
OxycontinOxycodone Hcl12$23,638
GemtesaVibegron27$22,912
TrulicityDulaglutide23$21,196
JanumetSitagliptin Phos/Metformin Hcl15$14,872
LinzessLinaclotide43$10,172
Lantus SolostarInsulin Glargine,hum.Rec.Anlog111$6,352
Breo ElliptaFluticasone/Vilanterol16$5,708
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen191$5,267
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$5,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$492$219,906209 claims
MerckJanuvia, Janumet$115$98,13975 claims
Novo NordiskOzempic$128$59,93863 claims
Sumitomo Pharma America, Inc.Gemtesa$71$22,91227 claims
Lilly USA, LLCTrulicity$13$21,19623 claims
AbbVieLinzess$61$10,17243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Hanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →